a public good project by the
Synthesis
Company
of California

© 2026

Stewart Spies | doi.page

0 works0 citations0 h-index

Stewart Spies

Publications by Year

Research Areas

Radiopharmaceutical Chemistry and Applications, Medical Imaging Techniques and Applications, Medical Imaging and Pathology Studies, Advanced Radiotherapy Techniques, Monoclonal and Polyclonal Antibodies Research

Most-Cited Works

→ Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+B-Cell Non-Hodgkin's Lymphoma(1999)538 cited
→ Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial(2002)266 cited
→ Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma(2000)234 cited
→ Left ventricular function during and after right ventricular pacing(2004)225 cited
Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.(2003)
→ Research Reporting Standards for Radioembolization of Hepatic Malignancies(2011)198 cited
→

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma

(2001)

183 cited

→ Internal Pair Production of 90Y Permits Hepatic Localization of Microspheres Using Routine PET: Proof of Concept(2010)118 cited

Serial assessment of left ventricular performance following coronary artery bypass grafting. Early postoperative results with myocardial protection afforded by multidose hypothermic potassium crystalloid cardioplegia.(1981)

Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.(1999)